Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Gamma-Glutamyl Transpeptidase È°¼º µµÀÇ ÀÓ»ó Áø´ÜÀû ÀÇÀÇ¿¡ °üÇÑ ¿¬±¸ A Study on Clinical Diagnostic Value of Serum Gamma-Glutamyl Transpeptidase Activity

´ëÇѺ´¸®ÇÐȸÁö 1979³â 13±Ç 3È£ p.179 ~ 186
¾È¿ë¸ð, À̱ͳç, À̻■,
¼Ò¼Ó »ó¼¼Á¤º¸
¾È¿ë¸ð (  ) 
¿¬¼¼´ëÇб³ ÀÓ»óº´¸®Çаú

À̱ͳç (  ) 
¿¬¼¼´ëÇб³ ÀÓ»óº´¸®Çаú
À̻■ (  ) 
¿¬¼¼´ëÇб³ ÀÓ»óº´¸®Çаú

Abstract


The enzyme Gamma-Glutamyl Transpeptidase (¥ã-GT, EC 2.3.2.2.) is distributed
widely throughout the body, highest activities being present in the kidney, followed by
pancreas, liver, spleen, and brain. It catalyses transfer of the gamma-glutamyl group
from gama glutamyl peptides to other peptides or any of the common amino acids
except proline.
Since a group of Polish investigators first reported elevated ¥ã-GT activity in sere of
Patients with hepatic disease, a number of reports have appeared describing the
conditions in which there is an elevated serum ¥ã-GT activity. The level of ¥ã-GT has
been shown to be raised mainly in patients with hepato-biliary disease and to a lesser
extent in a number of other conditions as Pancreatic, heart, neurologic, and renal
diseases.
As the Department of Clinical Pathology, Yonsei University Medical College, has
recently purchased the autoanalyzer System 5 (Gilford Instrument Laboratories, Inc.), the
rapid and_accurate determination of serum ¥ã-GT activity has ben made possible. The
author measured he activity in sera from the patients with a variety of diseases and 30
normal controls comprised of healthy medical students by using System 5.
The results are as follows.
1. The average values of ¥ã-GT for normal controls were 19.2 IU/L (range 8-33 IU/L)
in male, and 16.5 IU/L (range 6-28 IV/L) in female, respectively.
2. Patients with all forms of hepato-biliary diseases had elevated serum ¥ã-GT level.
The highest activity was noted in patients with cholecystits or cholelithiasis. .
3. Patients with primary hepatocellular and metastatic carcinomas had significantly
elevated serum ¥ã-GT level and higher increase rate than those of. any other enzyme
tests. This may suggest the value of ¥ã-GT as a screening test for neoplastic diseases
of the liver.
4. Of all the patients studied, patients with carcinoma of pancreas revealed highest ¥ã
-GT values.
5. Patients with carcinomas except hepatocellular and pancreatic carcinomas did not
reveal significant elevation of serum ¥ã-GT activity.
6. In patients with bone diseases, ¥ã-GT levels were within normal range in contrast to
elevated alkaline phosphatase activities.
7. A portion of patients with neurologic diseases showed slightly elevated ¥ã-GT level
No significant change of ¥ã-GT activity was noted in patients with renal failure.
8. In spite of the lack of specificity, it appears that the determination of ¥ã-GT can
indicate hepato-biliary dysfunction, especially used with other tests.
9. When the level of ¥ã-GT is increased abruptly during the follow-up of a liver
cirrhosis patient, the measurement of ¥ã-GT may indicate the progress of liver cirrhosis
or complication of hematoma, especially in a country like Korea which has a high
incidence of liver

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS